Risultati per: Linee guida Diverticolosi e Malattia diverticolare del colon

Al lavoro un team del Giovanni XXIII di Bergamo e del Bambino Gesù

Comunicato del 22/01/2025 n°1

Studio guidato dalle Molinette di Torino. Ruolo rare mutazioni

Background
Tumourigenesis in right-sided and left-sided colons demonstrated distinct features.

Objective
We aimed to characterise the differences between the left-sided and right-sided adenomas (ADs) representing the early stage of colonic tumourigenesis.

Design
Single-cell and spatial transcriptomic datasets were analysed to reveal alterations between right-sided and left-sided colon ADs. Cells, animal experiments and clinical specimens were used to verify the results.

Results
Single-cell analysis revealed that in right-sided ADs, there was a significant reduction of goblet cells, and these goblet cells were dysfunctional with attenuated mucin biosynthesis and defective antigen presentation. An impairment of the mucus barrier led to biofilm formation in crypts and subsequent bacteria invasion into right-sided ADs. The regions spatially surrounding the crypts with biofilm occupation underwent an inflammatory response by lipopolysaccharide (LPS) and an apoptosis process, as revealed by spatial transcriptomics. A distinct S100A11+ epithelial cell population in the right-sided ADs was identified, and its expression level was induced by bacterial LPS and peptidoglycan. S100A11 expression facilitated tumour growth in syngeneic immunocompetent mice with increased myeloid-derived suppressor cells (MDSC) but reduced cytotoxic CD8+ T cells. Targeting S100A11 with well-tolerated antagonists of its receptor for advanced glycation end product (RAGE) (Azeliragon) significantly impaired tumour growth and MDSC infiltration, thereby boosting the efficacy of anti-programmed cell death protein 1 therapy in colon cancer.

Conclusion
Our findings unravelled that dysfunctional goblet cells and consequential bacterial translocation activated the S100A11-RAGE axis in right-sided colon ADs, which recruits MDSCs to promote immune evasion. Targeting this axis by Azeliragon improves the efficacy of immunotherapy in colon cancer.

Ripristinata la capacità del bimbo di smaltire l’ammoniaca

Da esperti nuovo metodo diagnosi per cure sempre più su misura 

Rischio più alto per donne; attesi 1 milione di nuovi casi annui

Condizione rara, ma grave, causata da depositi di proteine anomale

Studio, dieta anti cancro da cereali integrali e verdura

Studio, dieta anti cancro da cereali integrali e verdura

The prospect of avoiding an invasive colonoscopy has helped fuel interest around new less-invasive alternatives to colorectal cancer screenings, such as stool-based tests and cell-free blood-based DNA tests, which received approval from the US Food and Drug Administration (FDA) this past July. But traditional colonoscopies remain the best method for catching colorectal cancer early, according to a study published in the Annals of Internal Medicine.

Il programma viene esteso fino alla fascia 70-74 anni